ReviewArthritis research & therapy2009
Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?
Review in Arthritis research & therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 40 citations in OpenAlex.
- Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis.European journal of pediatrics · 2023Article
- Duration of prednisone treatment before development ofJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2022Article
- Risk factors for cytomegalovirus reactivation in patients with kidney disease under immunosuppressive therapy.Clinical and experimental nephrology · 2022Article
- [Pneumocystis jirovecii pneumonia-an opportunistic infection undergoing change].Der Internist · 2019Review
- Risk factors for infectious complications of ANCA-associated vasculitis: a cohort study.BMC nephrology · 2018Article
- Review
- [Pneumocystis jirovecii pneumonia in patients with autoimmune diseases].Zeitschrift fur Rheumatologie · 2017Review
- Lung involvement in childhood onset granulomatosis with polyangiitis.Pediatric rheumatology online journal · 2017Review
- Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.Current treatment options in rheumatology · 2017Review
- [Treatment strategies for ANCA-associated vasculitides].Zeitschrift fur Rheumatologie · 2015Review
- Complications of long-term therapy for ANCA-associated systemic vasculitis.Nature reviews. Nephrology · 2012Review
- [Esophagitis during immunosuppression].Zeitschrift fur Rheumatologie · 2012Article
- Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.Drugs & aging · 2011Review
- [Development of morbidity and mortality in ANCA-associated vasculitis].Zeitschrift fur Rheumatologie · 2011Review
- Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides.Arthritis research & therapy · 2011Review
- Pneumocystis jiroveci pneumonia in giant cell arteritis: A case series.Arthritis care & research · 2011Article
- Update on the diagnosis and treatment of Pneumocystis pneumonia.Therapeutic advances in respiratory disease · 2011Review
- Recent advances in anti-neutrophil cytoplasmic antibody-associated vasculitis.Indian journal of nephrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although infections are a major concern in patients with primary systemic vasculitis, actual knowledge about risk factors and evidence concerning the use of anti-infective prophylaxis from clinical trials are scarce. The use of high dose glucocorticoids and cyclophosphamide pose a definite risk for infections. Bacterial infections are among the most frequent causes of death, with Staphylococcus aureus being the most common isolate. Concerning viral infections, cytomegalovirus and varicella-zoster virus reactivation represent the most frequent complications. The only prophylactic measure that is widely accepted is trimethoprim/sulfamethoxazole to avoid Pneumocystis jiroveci pneumonia in small vessel vasculitis patients with generalised disease receiving therapy for induction of remission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.